Novo Nordisk has launched a multi-month subscription plan for Wegovy. It’s the “first and only” program of its kind, and the manufacturer says it can save users up to $1,200 a year.
The new program aims to reduce cost uncertainty for patients and allow them to continue using FDA-approved GLP-1 obesity treatments. The company said in a press release that eligible self-pay patients can enroll through select telehealth providers for “lower, more predictable monthly fees.”
“By offering predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program is designed to support a more manageable way for people to stay on track with their treatment and focus on achieving meaningful, sustainable weight loss results,” Ed Sinka, Novo Nordisk’s senior vice president of marketing and patient solutions, said in the announcement.
The new subscription plan comes as Novo Nordisk battles stiff competition from Eli Lilly’s obesity drug and versions of the drug sold through compounding pharmacies. Novo was the first to market both the injectable Wegovy and its pill WeGoby, but the company has since ceded its superior obesity market share in the U.S. to Lilly, Fierce Pharma reports.
Novo was the first to market both the injectable Wegovy and its tablet Wegovy, but the company has since ceded its lion’s share of the obesity market in the United States to Lilly.
Eligible patients can choose a 3-, 6-, or 12-month subscription, with lower monthly fees for longer treatment periods. Users can save up to $1,200 on injection pens with the following subscriptions:
- 3-month subscription: $329/month, savings of $240/year
- 6-month subscription: $299/month, savings of $600/year
- 12-month subscription: $249/month, savings of $1,200/year
The 7.2 mg dose will be added to the program later, according to the announcement.
Tablets of the drug, which went on sale in the U.S. in January, are also available through subscription plans. Here’s a breakdown of the annual savings of up to $600 using 9 mg and 25 mg doses with each subscription.
- 3-month subscription: $289/month, savings of $120/year
- 6-month subscription: $269/month, savings of $360/year
- 12-month subscription: $249/month, savings of $600/year
For the pill, eligible patients will pay $149 per month for the 1.5mg and 4mg doses. The price for the 4 mg dose will increase to $199 per month starting August 31st.
Patients will be able to enroll in subscription plans through Ro, WeightWatchers, LifeMD, Him & Hers, and Sesame. More telehealth providers will be announced at a later date, and patients are encouraged to contact providers directly for complete program terms.
